Company intelligence / Profile preview

Saving Patients' Lives Medical B.V.

Nijmegen, Netherlandsopenpr.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Currently conducting a Phase 3 clinical trial (PROSTAPROGRESS) for Ferrotran®, which has reached over 75% patient enrollment as of August 2023. The trial aims to verify the efficacy and safety of Ferrotran® for detecting lymph node metastases in prostate cancer patients.

Therapeutic areas: Oncology
Modalities: NanoparticlesIron oxide particles
Industry: Medical Imaging

Drug pipeline

1 asset

ferumoxtran

Phase 3

Indications: Prostate cancer, Head and neck cancer

Partnerships

NanoEcho (agreement for supply and application of Ferrotran®)

Beyond the preview

Go deeper on Saving Patients' Lives Medical B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saving Patients' Lives Medical B.V..

Explore the full profile